<DOC>
	<DOCNO>NCT02279823</DOCNO>
	<brief_summary>In proof-of-concept study , safety efficacy solution formulation investigate male subject androgenetic alopecia ( AGA ) twice daily application 26 week .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Efficacy CB-03-01 Solution , Comparator Solution Vehicle Solution Males With Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<criteria>Subject mild moderate androgenetic alopecia ( AGA ) temple vertex region Subject willing maintain hairstyle , hair length , hair color throughout study Subject agree continue general hair care product regimen entire study Subjects sexually active female partner must surgically sterile agree use effective method birth control first administration test article 30 day last administration Subject dermatological disorder scalp target region possibility interfere application test article examination method , fungal bacterial infection , seborrheic dermatitis , psoriasis , eczema , folliculitis , scar , scalp atrophy Subject condition opinion investigator could interfere evaluation test article require use interfere topical systemic therapy ( e.g. , uncontrolled thyroid disease , certain genetic disorder involve hair growth pattern ) Subject current recent history ( within 3 month ) hair transplant , hair weave nonbreathable wig hair bond Subject current recent history ( within 3 month ) active hair loss due diffuse telogen effluvium , alopecia areata , scar alopecia , trichotillomania conditions/diseases AGA Subject current recent history ( within 3 month ) severe dietary change present history eat disorder ( ) Subject condition , investigator 's opinion , would make unsafe subject participate research study Subject currently enrol investigational drug device study Subject receive investigational drug treat investigational device within 30 day prior initiation treatment Subject unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function Subject may unreliable study include subject engage excessive alcohol intake drug abuse , subject unable return schedule followup visit The subject know hypersensitivity previous allergic reaction active inactive component test article tattoo ink Subject use follow topical preparation procedure scalp : Topical treatment include corticosteroid , pimecrolimus , tacrolimus , minoxidil , hormone therapy , antiandrogens agent know affect hair growth opinion investigator within 12 week initiation treatment Topical overthecounter ( OTC ) cosmetic treatment know reasonably believe affect hair growth ( e.g. , brand Aminexil , Maxilene , Nioxin , Foltene , etc . hair health hair growth product saw palmetto , copper , etc . ) opinion investigator within 4 week initiation treatment . Scalp procedure ( surgical , laser , light energy treatment , etc . ) within 6 month initiation treatment Subject use follow systemic medication procedure : Beta blocker , cimetidine , diazoxide , isotretinoin , vitamin A intake 10000 IU per day corticosteroid ( include intramuscular intralesional injection ) within 12 week initiation treatment . Inhaled , intranasal ocular corticosteroid allow use stable ( stable use define dose frequency unchanged least 4 week prior initiation treatment ) Retinoid , cyclosporine therapy within 6 month initiation treatment Finasteride ( PropeciaÂ® , etc . ) , dutasteride similar product ( ) within 12 month initiation treatment Chemotherapy , cytotoxic agent radiation ( scalp ) within 12 month initiation treatment Other systemic therapy may materially affect subject 's hair hair growth opinion investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>androgen</keyword>
	<keyword>alopecia</keyword>
	<keyword>CB-03-01</keyword>
	<keyword>solution</keyword>
	<keyword>topical</keyword>
</DOC>